Publicaciones en colaboración con investigadores/as de Hospital Universitario de Cruces (24)

2023

  1. Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases

    Neurologia, Vol. 38, Núm. 9, pp. 609-616

2021

  1. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

    Neurology, Vol. 97, Núm. 14, pp. E1367-E1381

2020

  1. Pandysautonomia and alpha-1 adrenergic receptor autoantibodies: a cause or a consequence? A case report

    Clinical Autonomic Research

2019

  1. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

    Parkinsonism and Related Disorders, Vol. 60, pp. 138-145

2018

  1. Anti-IgLON5 Disease Responsive to Immunotherapy: A Case Report with an Abnormal MRI

    Movement Disorders Clinical Practice, Vol. 5, Núm. 6, pp. 653-656

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  2. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson’s disease

    Journal of Neurology, Vol. 263, Núm. 5, pp. 895-905

  3. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

    Movement Disorders, Vol. 31, Núm. 5, pp. 742-747

2015

  1. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations

    Parkinsonism and Related Disorders, Vol. 21, Núm. 7, pp. 717-722

  2. Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension

    Journal of Human Hypertension, Vol. 29, Núm. 10, pp. 604-609

  3. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene

    Parkinsonism and Related Disorders, Vol. 21, Núm. 5, pp. 494-499

  4. Orthostatic Hypotension in Parkinson Disease: How Much You Fall or How Low You Go?

    Movement Disorders, Vol. 30, Núm. 5, pp. 639-645

2014

  1. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

    Movement Disorders, Vol. 29, Núm. 4, pp. 470-478

2013

  1. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers

    Parkinsonism and Related Disorders, Vol. 19, Núm. 10, pp. 906-909

  2. Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene

    Parkinsonism and Related Disorders, Vol. 19, Núm. 1, pp. 95-100

  3. Nocturnal hypertension and dysautonomia in patients with Parkinson's disease: Are they related?

    Journal of Neurology, Vol. 260, Núm. 7, pp. 1752-1756

  4. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease

    Clinical Neurology and Neurosurgery, Vol. 115, Núm. 8, pp. 1230-1233

2012

  1. SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy

    Parkinsonism and Related Disorders, Vol. 18, Núm. 1, pp. 45-48

  2. Trastorno de conducta del sueño REM y fallo autonómico ¿puro? A propósito de 2 casos

    Neurologia

2011

  1. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease

    Journal of Neurology, Vol. 258, Núm. 3, pp. 494-499